Sangamo Therapeutics announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Click here to view

Careers
Clinical Trials
Contact

Science
Programs
Patients
Investors & Media
- Overview
- News Releases
- Events
- Presentations
- ESG
About

Science
Programs
Patients
Investors & Media
- Overview
- News Releases
- Events
- Presentations
- ESG
About

LinkedIn
Twitter

Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology

Sign up for email alerts

Company

Science
Programs
Collaborations
Patients
About
Careers
Contact

Latest

News Releases
Events
Science Presentations
Scientific Publications
Corporate Presentations

Resources

Pipeline
Clinical Trials
Media Library
Legal Disclaimer
Privacy Policy

Social

LinkedIn
X

© 2025 Sangamo Therapeutics